(Q64952063)

1 July 2019

2 references

23 November 2020

29 April 2021

Biomarkers for tau pathology. (English)

1 reference

1 July 2019

positron emission tomography

main subject

1 reference

23 November 2020

2 references

23 November 2020

29 April 2021

1 reference

29 April 2021

1 reference

1

1 reference

1 July 2019

Henrik Zetterberg

series ordinal

6

object named as

Henrik Zetterberg

1 reference

1 July 2019

5

Kaj Blennow

1 reference

1 July 2019

7

William Jagust

1 reference

1 July 2019

3

Niklas Mattsson

1 reference

1 July 2019

Nicholas J Ashton

series ordinal

4

object named as

Nicholas J Ashton

1 reference

1 July 2019

author name string

Anne Maass

series ordinal

2

1 reference

1 July 2019

publication date

7 December 2018

1 reference

1 July 2019

Molecular and Cellular Neuroscience

1 June 2019

2 references

23 November 2020

29 April 2021

3 references

1 July 2019

23 November 2020

29 April 2021

97

1 reference

1 July 2019

page(s)

18-33

1 reference

1 July 2019

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

copyright license

2 references

23 November 2020

Neuropathological stageing of Alzheimer-related changes

29 April 2021

cites work

1 reference

12 December 2020

Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau)

1 reference

12 December 2020

Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease

1 reference

12 December 2020

Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease

1 reference

12 December 2020

Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease

1 reference

12 December 2020

Microtubule-associated protein tau. A component of Alzheimer paired helical filaments

1 reference

12 December 2020

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

1 reference

12 December 2020

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

12 December 2020

1 reference

12 December 2020

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

1 reference

12 December 2020

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

1 reference

12 December 2020

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

1 reference

12 December 2020

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease

1 reference

12 December 2020

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

1 reference

12 December 2020

CSF markers for incipient Alzheimer's disease

1 reference

12 December 2020

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

1 reference

12 December 2020

Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury.

1 reference

12 December 2020

Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory

1 reference

12 December 2020

Neuropathology of older persons without cognitive impairment from two community-based studies

1 reference

12 December 2020

Neurochemical aftermath of amateur boxing

1 reference

12 December 2020

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

1 reference

12 December 2020

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease

1 reference

12 December 2020

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain

1 reference

12 December 2020

Amyloid deposition is associated with impaired default network function in older persons without dementia

1 reference

12 December 2020

Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden

1 reference

12 December 2020

CSF biomarkers predict a more malignant outcome in Alzheimer disease.

1 reference

12 December 2020

Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations

1 reference

12 December 2020

Neuropathology of variants of progressive supranuclear palsy

1 reference

12 December 2020

Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau).

1 reference

12 December 2020

Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years

1 reference

12 December 2020

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

1 reference

12 December 2020

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

1 reference

12 December 2020

Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature

1 reference

12 December 2020

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings

1 reference

12 December 2020

Corruption and spread of pathogenic proteins in neurodegenerative diseases

1 reference

12 December 2020

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

1 reference

12 December 2020

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

1 reference

12 December 2020

Meta-analysis of amyloid-cognition relations in cognitively normal older adults

1 reference

12 December 2020

Plasma tau levels in Alzheimer's disease

1 reference

12 December 2020

Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease

1 reference

12 December 2020

Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein

1 reference

12 December 2020

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

1 reference

12 December 2020

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease

1 reference

12 December 2020

Pathology and sensitivity of current clinical criteria in corticobasal syndrome

1 reference

12 December 2020

Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry

1 reference

12 December 2020

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

1 reference

12 December 2020

Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

1 reference

12 December 2020

Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology

1 reference

12 December 2020

Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease

1 reference

12 December 2020

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study

1 reference

12 December 2020

Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease.

1 reference

12 December 2020

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

1 reference

12 December 2020

Cellular factors modulating the mechanism of tau protein aggregation

1 reference

12 December 2020

Proteomics of protein post-translational modifications implicated in neurodegeneration

1 reference

12 December 2020

Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia

1 reference

12 December 2020

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue

1 reference

12 December 2020

Identification of a major radiometabolite of [11C]PBB3.

1 reference

12 December 2020

Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks

1 reference

12 December 2020

Tau positron emission tomographic imaging in aging and early Alzheimer disease

1 reference

12 December 2020

Deep clinical and neuropathological phenotyping of Pick disease

1 reference

12 December 2020

Cascading network failure across the Alzheimer's disease spectrum

1 reference

12 December 2020

Tau and neurodegenerative disease: the story so far.

1 reference

12 December 2020

Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.

1 reference

12 December 2020

Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias

1 reference

12 December 2020

Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.

1 reference

12 December 2020

Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages

1 reference

12 December 2020

PET Imaging of Tau Deposition in the Aging Human Brain.

1 reference

12 December 2020

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

1 reference

12 December 2020

Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm

1 reference

12 December 2020

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

1 reference

12 December 2020

Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).

1 reference

12 December 2020

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

1 reference

12 December 2020

In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.

1 reference

12 December 2020

Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles

1 reference

12 December 2020

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging

1 reference

12 December 2020

An autoradiographic evaluation of AV-1451 Tau PET in dementia

1 reference

12 December 2020

Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies

1 reference

12 December 2020

In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum

1 reference

12 December 2020

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

1 reference

12 December 2020

Tau PET in Alzheimer disease and mild cognitive impairment.

1 reference

12 December 2020

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile

1 reference

12 December 2020

In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain

1 reference

12 December 2020

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy

1 reference

12 December 2020

Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly

1 reference

12 December 2020

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

1 reference

12 December 2020

Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.

1 reference

12 December 2020

[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration

1 reference

12 December 2020

Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

1 reference

12 December 2020

Plasma tau in Alzheimer disease

1 reference

12 December 2020

Defining imaging biomarker cut points for brain aging and Alzheimer's disease

1 reference

12 December 2020

Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy

1 reference

12 December 2020

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

1 reference

12 December 2020

Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology.

1 reference

12 December 2020

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy

1 reference

12 December 2020

Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy

1 reference

12 December 2020

In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317.

1 reference

12 December 2020

Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines

1 reference

12 December 2020

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

1 reference

12 December 2020

Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.

1 reference

12 December 2020

Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies

1 reference

12 December 2020

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

1 reference

12 December 2020

Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

1 reference

12 December 2020

Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease

1 reference

12 December 2020

Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study

1 reference

12 December 2020

Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition

1 reference

12 December 2020

Elevated 18F-AV-1451 PET tracer uptake detected in incidental imaging findings

1 reference

12 December 2020

Amyloid and tau PET demonstrate region-specific associations in normal older people.

1 reference

12 December 2020

Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease

1 reference

12 December 2020

Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline

1 reference

12 December 2020

A robust biomarker of large-scale network failure in Alzheimer's disease

1 reference

12 December 2020

Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals

1 reference

12 December 2020

Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals

1 reference

12 December 2020

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

1 reference

12 December 2020

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

1 reference

12 December 2020

Tau and amyloid β proteins distinctively associate to functional network changes in the aging brain

1 reference

12 December 2020

Quantification of Tau Load Using [(18)F]AV1451 PET.

1 reference

12 December 2020

Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks

1 reference

12 December 2020

Applying fluid biomarkers to Alzheimer's disease

1 reference

12 December 2020

The association between tau PET and retrospective cortical thinning in clinically normal elderly.

1 reference

12 December 2020

Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex

1 reference

12 December 2020

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease

1 reference

12 December 2020

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

1 reference

12 December 2020

[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging

1 reference

12 December 2020

Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography.

1 reference

12 December 2020

Cryo-EM structures of tau filaments from Alzheimer's disease.

1 reference

12 December 2020

Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging

1 reference

12 December 2020

Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers

1 reference

12 December 2020

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease

1 reference

12 December 2020

In vivo retention of 18F-AV-1451 in corticobasal syndrome.

1 reference

12 December 2020

AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure

1 reference

12 December 2020

Off-Target 18F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation.

1 reference

12 December 2020

Tau-imaging in neurodegeneration

1 reference

12 December 2020

Correlations of (18)F-THK5351 PET with post-mortem burden of tau and astrogliosis in Alzheimer's disease.

1 reference

12 December 2020

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.

1 reference

12 December 2020

[(18)F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP.

1 reference

12 December 2020

Preclinical Evaluation of (18)F-RO6958948, (11)C-RO6931643 and (11)C-RO6924963 as Novel Radiotracers for Imaging Aggregated Tau in AD with Positron Emission Tomography

1 reference

12 December 2020

Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden

1 reference

12 December 2020

Serum tau and neurological outcome in cardiac arrest.

1 reference

12 December 2020

Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case

1 reference

12 December 2020

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease

1 reference

12 December 2020

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.

1 reference

12 December 2020

Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.

1 reference

12 December 2020

Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum

1 reference

12 December 2020

Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data

1 reference

12 December 2020

MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([(18)F]-AV-1451) Binding.

1 reference

12 December 2020

Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease

1 reference

12 December 2020

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia

1 reference

12 December 2020

Flortaucipir F 18 Quantitation using a Parametric Estimate of Reference Signal Intensity (PERSI).

1 reference

12 December 2020

Entorhinal tau pathology, episodic memory decline and neurodegeneration in aging.

1 reference

12 December 2020

The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future

1 reference

12 December 2020

Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.

1 reference

12 December 2020

Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia

1 reference

12 December 2020

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.

1 reference

12 December 2020

Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy

1 reference

12 December 2020

The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.

1 reference

12 December 2020

Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample

1 reference

12 December 2020

Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.

1 reference

12 December 2020

Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.

1 reference

12 December 2020

Networks of tau distribution in Alzheimer's disease

1 reference

12 December 2020

Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease

1 reference

12 December 2020

[18 F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease

1 reference

12 December 2020

Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals

1 reference

12 December 2020

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.

1 reference

12 December 2020

PET imaging of tau protein targets: a methodology perspective.

1 reference

12 December 2020

Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.

1 reference

12 December 2020

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.

1 reference

12 December 2020

Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake.

1 reference

12 December 2020

Longitudinal tau PET in ageing and Alzheimer's disease.

1 reference

12 December 2020

18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.

1 reference

12 December 2020

18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal.

1 reference

12 December 2020

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

1 reference

12 December 2020

Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling.

1 reference

12 December 2020

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

1 reference

12 December 2020

Subthreshold Amyloid Predicts Tau Deposition in Aging

1 reference

12 December 2020

Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.

1 reference

12 December 2020

Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects

1 reference

12 December 2020

Dual tracer tau PET imaging reveals different molecular targets for C-THK5351 and C-PBB3 in the Alzheimer brain

1 reference

12 December 2020

From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease

1 reference

12 December 2020

Tau Kinetics in Neurons and the Human Central Nervous System

1 reference

12 December 2020

In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls

1 reference

12 December 2020

Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants.

1 reference

12 December 2020

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding.

1 reference

12 December 2020

Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology.

1 reference

12 December 2020

Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles

1 reference

12 December 2020

Update on biomarkers for amyloid pathology in Alzheimer's disease

1 reference

12 December 2020

Relationships Between Tau and Glucose Metabolism Reflect Alzheimer’s Disease Pathology in Cognitively Normal Older Adults

1 reference

12 December 2020

Alzheimer's disease drug development pipeline: 2018.

1 reference

12 December 2020

No association of salivary total tau concentration with Alzheimer's disease

1 reference

12 December 2020

In vivo quantification of neurofibrillary tangles with [F]MK-6240

1 reference

12 December 2020

Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease

1 reference

12 December 2020

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake

1 reference

12 December 2020

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study

1 reference

12 December 2020

A novel partial volume correction method for accurate quantification of [F] flortaucipir in the hippocampus

1 reference

12 December 2020

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

1 reference

12 December 2020

10.1016/J.MCN.2018.12.001

Identifiers

DOI

1 reference

1 July 2019

PMC publication ID

6584358

1 reference

1 July 2019

PubMed publication ID

30529601

1 reference

1 July 2019